Since 1996 WHN is the second oldest medical website on the net, second only to the American Medical Association, servicing over 35,000 physicians and scientists worldwide.
Non-Profit Trusted Source of Non-Commercial Health Information
Experts in functional psychiatry and neuroscience, cofounders of specialty-leading companies, and pioneers in psychedelic-assisted therapy gathered in Miami, FL, at the start of the month to kick off A4M’s inaugural State Of-Mind: A New Era in Psychedelic Medicine conference. Joining them were hundreds of visionary practitioners eager to learn how to leverage the rising potential …
Reporting live from Miami Beach, A4M hosted hundreds of modern medicine’s leading game-changers over the March 1-3 weekend at the March Symposium. We’re thrilled to be amongst such an inspiring crowd of renowned experts, pioneering researchers, and dedicated practitioners committed to elevating their knowledge, practice, and patient outcomes — a thriving community we are honored …
The global mental health crisis continues escalating at an alarming pace. Depression and anxiety alone currently cost the world economy $1 trillion annually. Experts project this economic burden could swell to a staggering $6-16 trillion by 2030 as rates of mental illness proliferate across the globe. In the United States, mental health conditions already rank …
These are the findings of a new analysis of brain scans from close to 60 people receiving treatment for depression, led by Imperial College London’s Centre for Psychedelic Research. The team behind the study believes it may have untangled how psilocybin exerts its therapeutic effects on the brain. Psilocybin is one of a number of …
Previous studies by Johns Hopkins Medicine researchers showed that psychedelic treatment with psilocybin relieved major depressive disorder symptoms in adults for up to a month. Now, in a follow-up study of those participants, the researchers report that the substantial antidepressant effects of psilocybin-assisted therapy, given with supportive psychotherapy, may last at least a year for …
The psychedelic drug psilocybin, a naturally occurring compound found in some mushrooms, has been studied as a potential treatment for depression for years. But exactly how it works in the brain and how long beneficial results might last is still unclear. In a new study, Yale researchers show that a single dose of psilocybin given …
Anxiety and depression are two of the most common mental disorders. According to the World Health Organization, depression alone affects more than 264 million people globally. Anxiety is even more prevalent, affecting over 40 million adults in the United States alone. Fortunately, there are numerous treatment options for anxiety and depression, ranging from conventional medications …
London based biotech Compass Pathways has successfully raised $80 million to bring its psilocybin therapy towards phase 3 development and prepare for trials; the drug is the active ingredient in magic mushrooms and it is being advanced for possible investigation of use in those with treatment resistant depression. Psilocybin has been studied in the past …
Magic mushrooms are fungi that contains the active compound psilocybin, which is a known hallucinogen that affects the part of the brain responsible for cognition, perception, and mood; psilocybin is being investigated for the effects on mental health and the possible potential to address various mental health conditions. These are wild mushrooms that can be …
In a landmark vote of 50.6% to 49.4% (89,320 for and 87,341 against, margin of 1,979) of the 176,000 residents of Denver, Colorado passed a ballot, Initiative 301, that decriminalizes psilocybin “magic” mushrooms. This vote will not make them become available in dispensaries, they will still remain on Schedule 1 classification under Federal law, rather …